Post-OTC Review Conditions Covered Under Proposed Monograph Procedures
This article was originally published in The Tan Sheet
Executive Summary
Companies seeking monograph status of OTC drugs marketed in the U.S. after the beginning of the OTC review would have to follow FDA's proposed new procedures for additional OTC conditions.